In a patient with acute ischemic stroke and an active gastrointestinal bleed, should aspirin be continued and how should antiplatelet therapy be managed?

Management of Aspirin in Acute Ischemic Stroke with Active GI Bleeding

In a patient with acute ischemic stroke and active gastrointestinal bleeding, aspirin should be temporarily withheld until hemostasis is achieved, then restarted as soon as bleeding is controlled—typically within 5 days maximum—because the mortality risk from recurrent stroke and thrombotic events substantially outweighs the bleeding risk once the acute hemorrhage is managed.

Immediate Management During Active Bleeding

Withhold Aspirin Temporarily

• Stop aspirin immediately when active GI bleeding is identified 1
• The priority is achieving hemostasis through endoscopic or radiological intervention
• Do not delay endoscopy or intervention to correct coagulopathy 1

Critical Timeframe Considerations

The stroke itself creates a hypercoagulable state with peak recurrent stroke risk in the first 48 hours 2, 3. However, active bleeding takes precedence over immediate antiplatelet therapy during the acute hemorrhage phase.

Timing of Aspirin Restart

Restart Within 5 Days Maximum

Aspirin must be restarted within 5 days of discontinuation to prevent catastrophic thrombotic events 1. This represents the optimal balance between rebleeding and thrombosis risk.

Evidence Supporting Early Restart

• A retrospective study of 118 patients showed that permanently discontinuing antithrombotic therapy after GI bleeding resulted in:
  • Hazard ratio of 5.77 for thrombotic events 1
  • Hazard ratio of 3.32 for mortality 1
• A prospective RCT of 156 patients with upper GI bleeding demonstrated:
  • Mortality reduction with continued aspirin: 1.3% vs 12.9% in placebo 1
  • Increased rebleeding (10.3% vs 5.4%) but zero fatal bleeds 1
  • Five deaths from thromboembolic events in the placebo group 1

Dosing Strategy Upon Restart

Initial Dose

• 160-325 mg loading dose when restarting 2, 4
• This ensures rapid platelet inhibition given the high early recurrent stroke risk

Maintenance Dose

• 75-100 mg daily for long-term secondary prevention 2, 5
• Lower maintenance doses (75-100 mg) provide equivalent stroke prevention with potentially less GI toxicity compared to higher doses 6

Mandatory Gastroprotection

Proton Pump Inhibitor Co-Prescription

A PPI must be prescribed concurrently with aspirin restart 1. This is not optional—it is essential for preventing recurrent bleeding 7.

• PPIs are recommended for the duration of antiplatelet therapy in patients with prior GI bleeding 1
• The case literature documents preventable severe bleeding events when PPIs are omitted 7

Alternative Antiplatelet Considerations

If Aspirin Cannot Be Restarted

If bleeding remains uncontrolled or recurs with aspirin:

• Clopidogrel 75 mg daily is the preferred alternative 8, 9
• Clopidogrel has lower GI bleeding risk compared to aspirin 10
• This is appropriate for patients with aspirin intolerance due to GI side effects 8

Avoid Dual Antiplatelet Therapy

• Do not use aspirin plus clopidogrel in patients with recent GI bleeding 2, 8
• DAPT increases bleeding risk without sufficient benefit in this context (extracranial bleeding 0.9% vs 0.4% with monotherapy) 11

Coordination of Care

Multidisciplinary Approach Required

• Consult gastroenterology urgently for endoscopic hemostasis 1
• Coordinate with cardiology/neurology regarding antiplatelet timing 1
• Document a clear plan for antiplatelet restart before discharge 1

Common Pitfalls to Avoid

1. Never permanently discontinue aspirin after GI bleeding without a documented plan—this triples mortality risk 1

2. Do not delay beyond 5 days for aspirin restart once hemostasis is achieved—thrombotic risk escalates dramatically 1

3. Do not restart aspirin without PPI co-prescription—this invites preventable rebleeding 7

4. Do not use higher aspirin doses (>150 mg daily) for maintenance—they increase GI toxicity without additional stroke prevention benefit 6

5. Do not substitute anticoagulation for antiplatelet therapy in non-cardioembolic stroke—aspirin is the evidence-based choice 2, 3

Special Populations

Patients Unable to Swallow

• Rectal aspirin 325 mg daily via suppository 11, 4
• Aspirin 80 mg daily via enteral tube 11, 4
• Clopidogrel 75 mg daily via enteral tube 11, 4

High-Risk Anatomic Features

If endoscopy reveals high-risk lesions (visible vessel, adherent clot):

• Delay aspirin restart by 24-48 hours beyond initial hemostasis
• Ensure PPI therapy is optimized (twice daily dosing may be considered)
• Plan close outpatient follow-up

Long-Term Monitoring

The incidence of major GI bleeding peaks at 19.2 per 100 person-years in the first month post-stroke, then decreases to approximately one-sixth by year 2 12. Patients require:

• Regular assessment for anemia
• Monitoring renal function (eGFR <60 increases bleeding risk) 12
• Continued PPI therapy indefinitely 1